Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Nuvation Bio (NYSE:NUVB)‘s stock had its “outperform” rating reissued by equities research analysts at Royal Bank Of Canada in a research report issued on Tuesday,Benzinga reports. They presently have a $20.00 price target on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 319.73% from the stock’s previous close.

NUVB has been the subject of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Nuvation Bio in a research note on Tuesday. Truist Financial set a $13.00 price objective on shares of Nuvation Bio in a research note on Tuesday, January 27th. UBS Group reduced their price objective on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research note on Tuesday, April 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Nuvation Bio currently has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Nuvation Bio Stock Performance

Shares of NUVB traded up $0.36 during trading hours on Tuesday, hitting $4.77. The company’s stock had a trading volume of 6,565,769 shares, compared to its average volume of 4,891,869. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -7.98 and a beta of 1.51. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.95 and a quick ratio of 6.81. The business has a 50 day simple moving average of $4.72 and a two-hundred day simple moving average of $5.92. Nuvation Bio has a 52-week low of $1.57 and a 52-week high of $9.75.

Nuvation Bio (NYSE:NUVB) last posted its earnings results on Monday, May 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.04. The firm had revenue of $83.23 million during the quarter, compared to the consensus estimate of $65.73 million. Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. On average, equities analysts expect that Nuvation Bio will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Nuvation Bio news, insider Kerry Wentworth sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $4.52, for a total value of $904,000.00. Following the completion of the transaction, the insider owned 53,000 shares of the company’s stock, valued at $239,560. The trade was a 79.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $5.02, for a total transaction of $251,000.00. Following the completion of the transaction, the insider directly owned 18,000 shares of the company’s stock, valued at approximately $90,360. This represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 286,750 shares of company stock valued at $1,339,118. Corporate insiders own 30.11% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

A number of hedge funds have recently made changes to their positions in NUVB. Vanguard Group Inc. grew its holdings in shares of Nuvation Bio by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock valued at $139,378,000 after purchasing an additional 101,011 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after purchasing an additional 1,298,131 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Nuvation Bio by 19.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock valued at $12,276,000 after purchasing an additional 551,508 shares during the last quarter. Aisling Capital Management LP grew its holdings in shares of Nuvation Bio by 16.5% during the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock valued at $10,954,000 after purchasing an additional 419,650 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Nuvation Bio by 852.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after purchasing an additional 2,424,109 shares during the last quarter. 61.67% of the stock is currently owned by institutional investors.

More Nuvation Bio News

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set an $11.00 price target — signaling sizable upside from current levels and likely supporting buying interest. Benzinga
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and raised its price target to $17.00, which is a bullish endorsement that may attract growth-oriented investors. Benzinga
• Positive Sentiment: Company Q1 results showed revenue of $83.2M (above consensus) and reported net product revenues of $18.5M for IBTROZI, with management highlighting launch momentum and adoption in first-line ROS1+ NSCLC — these operational signs and a cash balance of ~$533.7M underpin near-term execution and funding. PR Newswire
• Neutral Sentiment: Q1 2026 earnings call transcript is available for investors who want detail on guidance, commercialization cadence and pipeline development — useful for assessing sustainability of the revenue beat and management commentary. Earnings Call Transcript
• Negative Sentiment: Zacks reported that Nuvation missed its Q1 EPS estimate (reported $0.01 vs. Zacks’ $0.12), which could temper enthusiasm among earnings-focused traders and explains some of the mixed market reactions. Zacks
• Negative Sentiment: Despite the revenue beat, the company still shows deep historical losses (large negative net margin and negative ROE), which keeps valuation and profitability questions in play for longer-term investors. MarketBeat

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.